New study shows a minimum dose of hydromethylthionine could slow cognitive decline and brain atrophy in mild-to-moderate Alzheimer’s disease

ABERDEEN, Scotland and Singapore, 26 November, 2019 – In a paper published in today’s online issue of the Journal of Alzheimer’s Disease, TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s disease. These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy. Read more here . New study shows a minimum dose In a paper published in today’s online issue of the Journal of Alzheimer’s Disease, TauRx has reported unexpected results of a pharmacokinetic. Download

The release as fetched from its publisher. taurx.com ↗